Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis

被引:5
|
作者
Nemoto, Masahiro [1 ,2 ]
Zaizen, Yoshiaki [3 ]
Kataoka, Kensuke [4 ]
Kuroda, Kishio [3 ]
Tabata, Kazuhiro [3 ]
Bychkov, Andrey [3 ,5 ]
Sumikawa, Hiromitsu [6 ]
Johkoh, Takeshi [7 ]
Aoshima, Masahiro [1 ]
Kondoh, Yasuhiro [4 ]
Fukuoka, Junya [3 ,5 ]
机构
[1] Kameda Med Ctr, Dept Pulm Med, Kamogawa, Japan
[2] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan
[3] Nagasaki Univ, Dept Pathol, Grad Sch Biomed Sci, Nagasaki, Japan
[4] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Japan
[5] Kameda Med Ctr, Dept Pathol, Kamogawa, Japan
[6] Sakai City Med Ctr, Dept Diagnost Radiol, Sakai, Osaka, Japan
[7] Kinki Cent Hosp Mutual Aid Assoc Publ Sch Teacher, Dept Radiol, Itami, Hyogo, Japan
来源
PLOS ONE | 2021年 / 16卷 / 01期
关键词
INTEROBSERVER AGREEMENT; ALVEOLAR PROTEINOSIS; DIAGNOSIS; FEATURES; MULTIDISCIPLINARY; CLASSIFICATION;
D O I
10.1371/journal.pone.0245147
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and did not respond to nintedanib. Methods This study retrospectively examined the clinicoradiopathologic features of 40 consecutive patients with surgical lung biopsy-confirmed idiopathic pulmonary fibrosis treated with nintedanib. Additionally, we compared the histopathologic scoring of 21 microscopic features between patients with functional or radiological progression and those with non-progression during 12 months of treatment. Results The histopathologic evaluation showed edematous changes in the interlobular septum as the only histologic finding observed more frequently in patients with both functional and radiological progression than in those without (58% vs. 14%, P = 0.007 and 50% vs. 0%, P = 0.003, respectively). Regarding per-year change, patients with edematous changes in the interlobular septum showed greater progression in median changes in spared area (-12%, interquartile range: [-25%--5%], vs. -3% [-7%-0%], P = 0.004) and reticular shadow (7% [3%-13%], vs. 0% [0%-5%], P = 0.041) on computed tomography. Functional and radiological progression-free survival were shorter in patients with edematous changes in the interlobular septum than in those without (6.6 months, 95% confidence interval: [5.9-25.3], vs. event <50%, [12.1-Not available], P = 0.0009, and 6.1 months, [5.2-6.6] vs. 14.5 months [7.8-not available], P<0.0001). Conclusions Edematous changes in the interlobular septum may indicate poor nintedanib efficacy in idiopathic pulmonary fibrosis. Further studies are needed to validate these findings and address the mechanism behind ECIS.
引用
下载
收藏
页数:12
相关论文
共 50 条
  • [21] Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
    Antonio Rodriguez-Portal, Jose
    DRUGS IN R&D, 2018, 18 (01) : 19 - 25
  • [22] Efficacy of nintedanib in a patient with acute exacerbation of idiopathic pulmonary fibrosis
    Lv, Chengna
    Guo, Lun
    Tang, Pan
    Deng, Zaichun
    Ding, Qunli
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2022, 83 (03)
  • [23] Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
    José Antonio Rodríguez-Portal
    Drugs in R&D, 2018, 18 : 19 - 25
  • [24] Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
    Kolb, Martin
    Raghu, Ganesh
    Wells, Athol U.
    Behr, Juergen
    Richeldi, Luca
    Schinzel, Birgit
    Quaresma, Manuel
    Stowasser, Susanne
    Martinez, Fernando J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18): : 1722 - 1731
  • [25] Nintedanib Treatment for Elderly Patients with Idiopathic Pulmonary Fibrosis
    Ochi, Y.
    Kato, M.
    Sasaki, S.
    Nakamura, T.
    Yamada, T.
    Ihara, H.
    Takahashi, F.
    Takahashi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [26] Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Reply
    Costabel, Ulrich
    Stansen, Wibke
    Stowasser, Susanne
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (09) : 1275 - 1275
  • [27] NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: SAFETY AND TOLERABILITY
    Glaspole, I
    Lancaster, L.
    Hernandez, P.
    Inoue, Y.
    Wachtlin, D.
    Loaiza, L.
    Conoscenti, C.
    Quaresma, M.
    Stowasser, S.
    Richeldi, L.
    RESPIROLOGY, 2019, 24 : 34 - 34
  • [28] Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis
    Schmid, Ulrike
    Doege, Christiane
    Dallinger, Claudia
    Freiwald, Matthias
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 : 136 - 143
  • [29] Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Subgroup Analyses by TORVAN Stage
    Torrisi, S.
    Wijsenbeek, M.
    Orsatti, L.
    Quaresma, M.
    Schinzel, B.
    Kreuter, M.
    Vancheri, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [30] Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
    Ian Glaspole
    Francesco Bonella
    Elena Bargagli
    Marilyn K. Glassberg
    Fabian Caro
    Wibke Stansen
    Manuel Quaresma
    Leticia Orsatti
    Elisabeth Bendstrup
    Respiratory Research, 22